NASDAQ: IMNNImunon Inc Stock
$1.44+0.14 (+10.77%)
Updated Apr 25, 2024
IMNN Price
$1.44
Fair Value Price
$0.47
Market Cap
$13.54M
52 Week Low
$0.48
52 Week High
$2.00
P/E
-0.67x
P/B
1.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$19.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.64
Operating Cash Flow
-$19M
Beta
0.66
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IMNN Overview
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMNN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMNN ($1.44) is overvalued by 209.11% relative to our estimate of its Fair Value price of $0.47 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMNN ($1.44) is not significantly undervalued (209.11%) relative to our estimate of its Fair Value price of $0.47 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMNN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMNN due diligence checks available for Premium users.
Be the first to know about important IMNN news, forecast changes, insider trades & much more!
IMNN News
Valuation
IMNN fair value
Fair Value of IMNN stock based on Discounted Cash Flow (DCF)
Price
$1.44
Fair Value
$0.47
Overvalued by
209.11%
IMNN ($1.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMNN ($1.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMNN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMNN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.67x
Industry
15.41x
Market
40.97x
IMNN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
5.8x
IMNN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMNN's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.9M
Profit Margin
0%
IMNN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.9M
Liabilities
$8.5M
Debt to equity
0.64
IMNN's short-term assets ($18.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMNN's short-term assets ($18.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMNN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
-$3.3M
Financing
$30.2k
IMNN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMNN vs Biotech Stocks
Imunon Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.